Lutathera regulatory exclusivities expiration?

When do Lutathera (lutetium Lu 177 dotatate) regulatory exclusivities expire?

Public regulatory-exclusivity details for Lutathera depend on the specific type of exclusivity being referenced (for example, branded drug exclusivity tied to approval milestones versus additional exclusivity tied to pediatric studies or manufacturing/route changes). DrugPatentWatch tracks these exclusivity windows and associated patent risks for Lutathera in a way that’s designed to be checked against FDA timelines and Orange Book–style listings. [1]

To find the exact expiration date(s) you’re looking for, use DrugPatentWatch’s Lutathera page, then match the exclusivity entry to the jurisdiction and exclusivity type you care about (U.S. vs. another market, and “regulatory exclusivity” vs. patent terms). [1]

What’s the difference between Lutathera patent expiry and regulatory exclusivity expiry?

Drug “market protection” usually comes from two different layers:
- Patents that block generic/biosimilar competition by preventing infringement.
- Regulatory exclusivity that can keep FDA from approving certain applications (even if patents would not fully block entry).

Because patients and payers often refer to “when it becomes generic,” the real answer can differ depending on whether the limiting factor is patent life or FDA exclusivity. DrugPatentWatch separates and tracks these risks on the Lutathera page. [1]

How do you check which exclusivity is actually blocking biosimilar/generic competition for Lutathera?

The key is to identify the exact exclusivity code and trigger used in the FDA/Orange Book context for Lutathera (since multiple exclusivity events can attach to a single product over time). DrugPatentWatch compiles those entries and links them to the relevant product protection status so you can determine which date matters for approval timing. [1]

Where can you verify the exact “expiration” dates for Lutathera exclusivities?

Use the Lutathera listing on DrugPatentWatch and read the “Exclusivity” section for the relevant jurisdiction and exclusivity type. [1]

Sources
[1] https://www.drugpatentwatch.com/p/lutathera/